SCHEMBL2480174

SCHEMBL2480174

[c]1nc2c(s1)CCc1ccccc1-2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 1/20 0.49
BCHE P06276 2/20 0.43
ACHE P22303 1/20 0.43
ATP4A P20648 1/20 0.42
ATP4B P51164 1/20 0.42
POLB P06746 3/20 0.41
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
HPGD P15428 2/20 0.40
LMNA P02545 1/20 0.40
ALOX12 P18054 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 3/20 0.40
CES1 P23141 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2480149 0.90 BCHE (0.46) ADORA1BCHEACHENPC1RAB9A
SCHEMBL666370 0.84 MAPK8 (0.49) ADORA1BCHEACHEKMT2AMEN1
SCHEMBL7576114 0.74 NOS2 (0.39) LMNADYRK1ACHEK1DAPK3LTK
SCHEMBL2477067 0.72 KDM4E (0.53) KMT2AMEN1NPC1RAB9AHPGD
SCHEMBL7118774 0.71 KDM4E (0.41) ADORA1BCHEACHEKMT2AMEN1
SCHEMBL2477193 0.70 KDR (0.40) KMT2AMEN1HPGDALOX12ALDH1A1
SCHEMBL4542398 0.69 ADORA1 (0.50) ADORA1ATP4AATP4BPOLBKMT2A
Dihydrophenanthrene SCHEMBL28876918 0.68 CES1 (0.65) NPC1RAB9AHPGDLMNAKDM4E
SCHEMBL1745165 0.67 ADORA1 (0.97) ADORA1ATP4AATP4BPOLBKMT2A
SCHEMBL30953833 0.67 ADORA1 (0.97) ADORA1ATP4AATP4BPOLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2350311-B1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS MADRIGAL PHARMACEUTICALS INC (US) 2013-12-25 EP claimed
US-8349857-B2 Quinazoline derivatives having tyrosine kinase inhibitory activity SHIONOGI & CO., LTD. (JP) 2013-01-08 US claimed
US-20070244130-A1 Compounds and Compositions as Ppar Modulators IRM LLC (BM) 2007-10-18 US claimed
US-20070203155-A1 Compounds And Compositions As Ppar Modulators IRM LLC (BM) 2007-08-30 US claimed
EP-1749003-A1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2007-02-07 EP claimed
EP-1748993-A1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2007-02-07 EP claimed
US-20060122387-A1 Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells CTI EUROPE S.R.L. 2006-06-08 US claimed
WO-2005116000-A1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2005-12-08 WO claimed
WO-2005116016-A1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2005-12-08 WO claimed
US-20040204477-A1 Interaction inhibitors of tcf-4 with beta-catenin PHARMACIA ITALIA S.P.A. (IT) 2004-10-14 US claimed
EP-1406889-A2 INTERACTION INHIBITORS OF TCF-4 WITH BETA-CATENIN Pharmacia Italia S.p.A. (IT) 2004-04-14 EP claimed
WO-2003105842-A1 DERIVATIVES OF CHROMEN-2-ONE AS INHIBITORS OF VEGF PRODUCTION IN MAMMALIAN CELLS NOVUSPHARMA S.P.A. (IT) 2003-12-24 WO claimed
WO-2003006447-A2 INTERACTION INHIBITORS OF TCF-4 WITH BETA-CATENIN PHARMACIA ITALIA SPA (IT) 2003-01-23 WO claimed
CN-114539167-A Process for producing alkynyl ketone derivative 盐野义制药株式会社 2022-05-27 CN disclosed
US-10130634-B2 Therapeutic agent for ophthalmic disease MITSUBISHI TANABE PHARMA CORPORATION (JP) 2018-11-20 US disclosed
US-9951051-B2 Process for producing alkynylketone derivative SHIONOGI & CO., LTD. (JP) 2018-04-24 US disclosed
EP-1361220-A1 CYCLIC COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM SHIONOGI & CO., LTD. (JP) 2003-11-12 EP disclosed
US-20030195231-A1 Compounds exhibiting thrombopoietin receptor agonism SHIONOGI & CO., LTD. (JP) 2003-10-16 US disclosed
WO-2003006447-A2 INTERACTION INHIBITORS OF TCF-4 WITH BETA-CATENIN PHARMACIA ITALIA SPA (IT) 2003-01-23 WO disclosed
EP-1253142-A1 COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM SHIONOGI & CO., LTD. (JP) 2002-10-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204477-A1 Interaction inhibitors of tcf-4 with beta-catenin TCF4, TCF7, TCF7L2 ADORA1 4204/4885BCHE 3033/4885ACHE 2113/4885
US-20070203155-A1 Compounds And Compositions As Ppar Modulators PPARG, PPARA, PPARD ADORA1 755/4885BCHE 3613/4885ACHE 3852/4885
US-20030195231-A1 Compounds exhibiting thrombopoietin receptor agonism MPL, TEK, NPY1R ADORA1 167/4885BCHE 4366/4885ACHE 4716/4885
US-10130634-B2 Therapeutic agent for ophthalmic disease MITF, UACA, VEGFA ADORA1 2368/4885BCHE 4380/4885ACHE 3632/4885
US-20070244130-A1 Compounds and Compositions as Ppar Modulators PPARG, PPARA, PPARD ADORA1 755/4885BCHE 3613/4885ACHE 3852/4885
US-20060122387-A1 Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells KDR, FLT1, VEGFA ADORA1 1733/4885BCHE 4822/4885ACHE 4803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.